Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
15Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
BioAge Labs, Inc. (BIOA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
24Total relationships
3Distinct source URLs
10High confidence
0.778Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
BioAge Labs, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CITIGROUP-GLOBAL-MARKETS-INC
CITIGROUP-GLOBAL-MARKETS-INC
92%
the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
GOLDMAN-SACHS-CO-LLC
GOLDMAN-SACHS-CO-LLC
92%
the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
PIPER-SANDLER-CO
PIPER-SANDLER-CO
92%
the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a …
SVB-INNOVATIVE-CREDIT-GROWTH-FUND-IX-LP-AND-INNO
SVB-INNOVATIVE-CREDIT-GROWTH-FUND-IX-LP-AND-INNO
92%
In May 2022, we entered into a loan and security agreement (the Loan Agreement) with SVB Innovative Credit Growth Fund IX, LP and Innovative Credit Growth Fund VIII-A, LP pursuant to which we were ab…
Reciprocal relationship from GPCR graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from GPCR g…
royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized under the Novartis Agreement in the three months ended March 31, 2026 and 2025. Duri…
Reciprocal relationship from NVSEF graph: Reciprocal relationship from BIOA graph: royalties on net sales of licensed products. Collaboration revenue of $2.8 million and $1.5 million was recognized u…
Reciprocal relationship from GPCR graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from GPCR graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from GPCR g…
novel APJ agonist antibody, as well as the filing of a U.S. provisional patent for novel small molecule APJ agonists. We intend to file the first Investigational New Drug application (IND) for an APJ…
Reciprocal relationship from LLY graph: Reciprocal relationship from BIOA graph: novel APJ agonist antibody, as well as the filing of a U.S. provisional patent for novel small molecule APJ agonists. …
MS-PE
Morgan Stanley
72%
Reciprocal relationship from MS-PE graph: Reciprocal relationship from BIOA graph: s, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately li…
s, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may still occur in the future. We regularly maintain cash balances at third…
Reciprocal relationship from MYGN graph: Reciprocal relationship from BIOA graph: ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in …
ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often invo…
SNYNF
Sanofi
72%
ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often invo…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from BIOA graph: ion of a new CDMO could negatively affect our ability to develop product candidates or commercialize our products in…
Reciprocal relationship from AMGN graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from BIOA graph: Reciprocal relationship from AMGN g…
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
, future revenue streams, research program or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financi…
NOVARTIS-PHARMA-AG
NOVARTIS-PHARMA-AG
62%
novel APJ agonist antibody, as well as the filing of a U.S. provisional patent for novel small molecule APJ agonists. We intend to file the first Investigational New Drug application (IND) for an APJ…
NVS
Novartis AG
62%
Reciprocal relationship from NVS graph: Reciprocal relationship from BIOA graph: novel APJ agonist antibody, as well as the filing of a U.S. provisional patent for novel small molecule APJ agonists. …
BioAge Labs, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BIOA-DEBT-8201
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
BIOA-DEBT
Debt stack $1.2M
90%
Market cache reports total debt of $1.2M.
BIOA-DEBT-8200
Warrants outstanding: 214000
90%
xbrl warrant detail from xbrl 2025-12-31.
BioAge Labs, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for BioAge Labs, Inc..
BioAge Labs, Inc. Ownership
Holder
Name
Confidence
Evidence
BIOA-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 146 tracked holders.
